Stock comparison
Corcept Therapeutics
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.01B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 71B | UTHR |
| Benjamin Graham | 86C | 76B | CORT |
| Philip Fisher | 64C | 76B | UTHR |
| Peter Lynch | 32F | 62C | UTHR |
| Joel Greenblatt | 47D | 46D | CORT |
| Charlie Munger | 60C | 64C | UTHR |
| Terry Smith | 68C | 64C | CORT |
Side-by-side metrics
| Metric | CORT | UTHR |
|---|---|---|
| Market cap | $6.01B | $24.13B |
| P/E (TTM) | 122.0x | 19.2x |
| EV/EBIT | 131.9x | 15.2x |
| ROIC (TTM) | -1.23% | 18.81% |
| Gross margin | 98.25% | 86.58% |
| Net margin | 6.23% | 40.61% |
| Revenue CAGR 5y | 20.1% | 17.22% |
| EPS CAGR 5y | -0.52% | 29.84% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Revenue CAGR 5y20.1%vs 17.22%+14%
- Gross margin98.25%vs 86.58%+12%
UTHR leads on
- ROIC (TTM)18.81%vs -1.23%+107%
- EPS CAGR 5y29.84%vs -0.52%+102%
- Debt / Equity-vs 0.0x+100%
- EV/EBIT15.2xvs 131.9x+88%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.